AWM
HRMY icon

Abound Wealth Management’s Harmony Biosciences HRMY Stock Holding History

Abound Wealth Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26
Closed -$840 – 1342
2023
Q4 		$840 Buy
+26
New +$726 ﹤0.01% 805

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Abound Wealth Management's HRMY Position: Q1 2024 in Review

Abound Wealth Management sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 26 shares — an estimated $840 sold.

Abound Wealth Management first reported a position in HRMY in Q4 2023 and held it in 1 quarter. The position peaked at $840 in Q4 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

  • Abound Wealth Management reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
  • Abound Wealth Management sold 26 Harmony Biosciences shares in Q1 2024, an estimated $840.
  • Abound Wealth Management first reported a position in Harmony Biosciences in Q4 2023 and held it in 1 quarter.
  • Abound Wealth Management's Harmony Biosciences position peaked at $840 in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Abound Wealth Management's 13F filing for Q1 2024, filed 8 Aug 2024.